

Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial

Katherine M.W. Pisters, Eric Vallières, John J. Crowley, Wilbur A. Franklin, Paul A. Bunn Jr, Robert J. Ginsberg†, Joe B. Putnam Jr, Kari Chansky, and David Gandara

ABSTRACT

Purpose

Patients with early-stage non–small-cell lung cancer (NSCLC) have a poor prognosis even after complete resection. Earlier studies of preoperative (induction) chemotherapy in resectable NSCLC demonstrated feasibility and encouraging survival data. This randomized phase III trial compared overall survival (OS) for preoperative paclitaxel and carboplatin followed by surgery with surgery alone in patients with early-stage NSCLC.

Patients and Methods

Patients with clinical stage IB-IIIa NSCLC (excluding superior sulcus tumors and N2 disease) were eligible. Patients were randomly assigned to surgery alone or to three cycles of paclitaxel (225 mg/m²) and carboplatin (area under curve, 6) followed by surgical resection. The primary end point was OS; secondary end points were progression-free survival (PFS), chemotherapy response, and toxicity.

Results

The trial closed early with 354 patients after reports of a survival benefit for postoperative chemotherapy in other studies. The median OS was 41 months in the surgery-only arm and 62 months in the preoperative chemotherapy arm (hazard ratio, 0.79; 95% CI, 0.60 to 1.06; $P = .11$.) The median PFS was 20 months for surgery alone and 33 months for preoperative chemotherapy (hazard ratio, 0.80; 95% CI, 0.61 to 1.04; $P = .10$.) Major response to chemotherapy was seen in 41% of patients; no unexpected toxicity was observed.

Conclusion

This trial closed prematurely after compelling evidence supporting postoperative chemotherapy emerged. Although OS and PFS were higher with preoperative chemotherapy, the differences did not reach statistical significance. At present, stronger evidence exists for postoperative chemotherapy in early-stage NSCLC.

J Clin Oncol 28:1843-1849. © 2010 by American Society of Clinical Oncology

INTRODUCTION

Lung cancer remains the most common cause of cancer-related death in men and women. Non–small-cell lung cancer (NSCLC) is the most common type, and it accounts for 85% of cases. Unfortunately, the majority of patients with NSCLC have metastatic disease at diagnosis. However, even patients with resectable disease have poor survival.

The need to improve survival rates in these patients prompted research exploring the role of systemic therapy in operable NSCLC. In the 1990s, several clinical trials of preoperative chemotherapy (also known as induction chemotherapy) followed by surgery or radiation in patients with locally

advanced NSCLC showed improvements in survival.¹⁻⁶ A phase II trial of preoperative paclitaxel and carboplatin chemotherapy established feasibility and safety with encouraging overall survival (OS) results in patients with early-stage NSCLC.^{7,8} These findings prompted this phase III trial of preoperative paclitaxel and carboplatin plus surgery or surgery alone in early-stage NSCLC.

PATIENTS AND METHODS

Study Design

This intergroup, randomized, phase III trial (S9900) compared three cycles of preoperative paclitaxel and carboplatin followed by surgery with surgery alone in patients

From the University of Texas M. D. Anderson Cancer Center, Houston, TX; Puget Sound Cancer Consortium, Swedish Cancer Institute; Southwest Oncology Group Statistical Center, Seattle, WA; University of Colorado Health Sciences Center, Denver, CO; University of Toronto, Toronto, Canada; Vanderbilt University Medical Center, Nashville, TN; and University of California, Davis, Cancer Center, Sacramento, CA.

†Deceased.

Submitted September 15, 2009; accepted December 22, 2009; published online ahead of print at www.jco.org on March 15, 2010.

Supported in part by PHS Cooperative Agreement Grants No. CA32102, CA38926, CA20319, CA46441, CA105409, CA42777, CA35192, CA46113, CA37981, CA76429, CA45377, CA12644, CA76447, CA46282, CA22433, CA58861, CA35261, CA58348, CA14028, CA74647, CA86780, CA04919, CA35090, CA35178, CA58416, CA58658, CA67575, CA63844, CA35119, CA35431, CA67663, and CA46136 from the National Cancer Institute; and by Bristol-Myers Squibb.

Presented in part at the 41st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, Orlando, FL; the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL; the 11th World Conference on Lung Cancer, International Association for the Study of Lung Cancer, July 3-6, 2005, Barcelona, Spain; and the 13th World Conference on Lung Cancer, International Association for the Study of Lung Cancer, July 31-August 4, 2009, San Francisco, CA.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical Trials repository link available on JCO.org.

Corresponding author: Katherine M.W. Pisters, MD, The University of Texas M. D. Anderson Cancer Center, PO Box 301402, Unit 432, Houston, TX 77230-1402; e-mail: kpisters@mdanderson.org.

© 2010 by American Society of Clinical Oncology

0732-183X/10/2811-1843/\$20.00

DOI: 10.1200/JCO.2009.26.1685

with clinical stage IB, II, or selected IIIA (excluding superior sulcus tumors and ipsilateral mediastinal lymph node involvement) NSCLC. The main objective was to compare OS. Secondary objectives were to compare progression-free survival (PFS), relapse patterns, operative morbidity and mortality, and chemotherapy response and toxicities. The protocol was approved by the institutional review boards at the participating institutions; all patients provided written informed consent. Data were collected, managed, and analyzed by the Southwest Oncology Group (SWOG) Data Operations Center at Cancer Research and Biostatistics. The SWOG Data and Safety Monitoring Committee oversaw the conduct of the study.

Eligibility Criteria

To be eligible for the trial, patients had to be ≥ 18 years old and have clinical stage T2N0, T1-2N1, or T3N0-1 NSCLC (based on cytology or pathology), as defined by history, physical examination, laboratory evaluation, chest computed tomography (CT), and bronchoscopy. Mediastinoscopy or biopsy (to rule out involvement) was required for adenopathy larger than 1.0 cm on CT. Clinical T stage was defined by CT findings. Clinical N stage was defined by mediastinoscopy and CT findings. N1 nodes were considered clinically involved if larger than 1.0 cm on CT. Patients were also required to have a Zubrod performance status of 0 or 1; adequate hematologic, renal, and hepatic function for chemotherapy and surgery; a predicted postresection forced expiratory volume in 1 second of ≥ 1.0 L; and measurable disease by RECIST (Response Evaluation Criteria in Solid Tumors).⁹

Pretreatment Evaluation

All patients underwent chest CT, chest x-ray, electrocardiography, pulmonary function tests, bronchoscopy, mediastinoscopy (when required by protocol), and laboratory tests. As it was not universally available at study initiation, positron emission tomography imaging was optional. Brain and bone imaging were performed if indicated.

Treatment Plan

After providing informed consent, patients were randomly assigned to either surgery alone (arm 1) or preoperative chemotherapy followed by surgery (arm 2). The randomization was stratified on clinical stage (IB/IIA v IIB/IIIA) using a dynamic balancing algorithm.

Surgery alone. Patients in arm 1 underwent surgery within 14 days after trial registration. Segmentectomy and wedge resection were discouraged, and a complete mediastinal lymph node dissection/sampling was recommended.

Preoperative chemotherapy plus surgery. Patients in arm 2 received paclitaxel (225 mg/m² given intravenously over 3 hours) and carboplatin (area under the curve of 6 given intravenously over 30 minutes after paclitaxel) every 21 days for three cycles. Before cycles 2 and 3, patients had a history, blood tests, and chest x-ray. Toxicities were graded using National Cancer Institute Common Toxicity Criteria, version 2.0. Chemotherapy was modified for toxicity as necessary. Within 2 to 6 weeks after cycle 3 of chemotherapy, patients were re-evaluated for surgery by a history, physical examination, chest CT, chest x-ray, electrocardiography, pulmonary function tests, and laboratory tests. Radiographic response was assessed using RECIST.⁹ Surgery occurred within 3 to 8 weeks after chemotherapy.

Follow-up. Patients were removed from protocol-based therapy and treated per their physicians if they had incomplete resection; N2, N3, T4, or M1 disease at surgery; or unacceptable toxicity. All patients were observed for recurrence, long-term toxicities, and survival. After protocol therapy was completed, follow-up visits, which included a history and chest imaging, were scheduled every 3 months for 1 year, every 6 months for the next 4 years, and then annually.

Statistical considerations. The primary objective was to compare OS between the two study arms (intent-to-treat analysis). The study was designed to detect a 33% increase in median OS (over an expected 2.7 years) with 81% power, using a one-sided .025 significance level, with an accrual goal of 300 patients per arm. OS was defined as the time between registration and death. PFS was defined as the time between registration and disease progression (defined radiographically before or after surgery or at surgery if more extensive disease) or death, whichever occurred first.

Estimates of median and survival rates were calculated by the Kaplan-Meier method. Survival comparisons were made using Cox proportional

hazards models, stratified by stage (IB/IIA v IIB/IIIA). Risk estimates for local and distant relapse were generated using cumulative incidence analyses with competing risk designation for death or disease progression to other sites.

The SWOG Data and Safety Monitoring Committee recommended early closure of the S9900 trial (S9900 closed July 1, 2004) after reports of an OS benefit from postoperative chemotherapy in patients with resected NSCLC.¹⁰⁻¹²

RESULTS

Patient Characteristics

Between October 1999 and June 2004, 354 patients were accrued. Seventeen patients were ineligible for the following reasons: surgery alone, incorrect stage (seven patients), no measurable disease (n = 3), and incorrect histology (n = 1); chemotherapy and surgery, missing required baseline bronchoscopy (n = 3), incorrect histology (n = 2), and incorrect stage (n = 1). Among eligible patients, 168 were randomly assigned to arm 1 (surgery alone) and 169 to arm 2 (preoperative chemotherapy and surgery; Fig 1). Baseline patient characteristics are summarized in Table 1. Known prognostic variables were well balanced between the two study arms.

Chemotherapy Compliance, Response, and Toxicity

Seventy-nine percent of patients assigned to receive chemotherapy completed all three planned cycles. Reasons for not completing chemotherapy included adverse effects (8%), refusal (3%), disease progression (2%), and death (2%). Chemotherapy response rates are presented in Appendix Table A1 (online only). The overall major response (complete or partial response) rate was 41%. Sixteen patients were not assessable for radiographic response because of improper or inadequate follow-up imaging (n = 8); chemotherapy refusal (n = 5); early chemotherapy discontinuation (n = 2); or delinquent data submission (n = 1).

Appendix Table A2 (online only) summarizes chemotherapy toxicities. Five patients were not assessable for toxicity (refused chemotherapy after random assignment); therefore, toxicity data were available for 164 patients. Grade 3 or 4 neutropenia occurred in 48%, but only 4% had febrile neutropenia. Grade 3 or 4 paclitaxel-induced hypersensitivity reactions occurred in 3%. Anemia and thrombocytopenia were uncommon. Fifty-one percent of patients had grade 1 or 2 fatigue or malaise, while only 4% experienced grade 3 fatigue.

There were three deaths during preoperative chemotherapy. One patient died at home from unknown causes on day 8 of cycle 1; one died on day 9 of cycle 2 from complications of a stroke, pneumonia, and neutropenia; and one died from congestive heart failure 51 days after cycle 2.

Surgery

One hundred sixty-five of 168 patients in the surgery-alone group underwent surgical exploration (Table 2), two refused surgery and one could not be intubated and did not have surgery. One hundred forty-six patients had complete resection (R0; 88% of those who had exploration and 87% of those randomly assigned to surgery alone), seven had microscopic residual disease (R1), five had gross residual disease (R2), and seven underwent exploration without resection. Four patients refused their randomly assigned treatment and received preoperative chemotherapy (a major protocol violation).

Preoperative Chemotherapy in Early NSCLC




Fig 1. CONSORT diagram for 354 registered patients. AUC, area under curve; q, every; ITT, intention to treat; pre-op, preoperative; PFS, progression-free survival.

Among the 169 patients in the preoperative chemotherapy and surgery group, 152 underwent surgical exploration. Reasons for not undergoing surgery included disease progression (n = 6); patient refusal (n = 5); death during preoperative therapy (n = 3); toxicity/

refusal (n = 1); and other (n = 2). One hundred forty-two patients had complete resection (R0; 93% of those who underwent exploration and 84% of those randomly assigned to arm 2), five had microscopic residual disease (R1), and five underwent exploration without resection. One patient who underwent R1 resection had refused preoperative chemotherapy and proceeded directly to surgery (major protocol

Table 1. Baseline Patient Characteristics

Characteristic	%	
	Surgery Alone (n = 168)	Preoperative Chemotherapy (n = 169)
Median age, years	64	65
Range	35-82	38-83
Sex		
Male	68	64
Female	32	36
Performance status		
0	63	66
1	37	34
Clinical stage		
IB/IIA	68	67
IIB/IIIA	32	33
Histology		
Squamous cell carcinoma	42	34
Adenocarcinoma	33	31
NSCLC, other*	23	29
Large cell carcinoma	2	6

Abbreviation: NSCLC, non-small-cell lung cancer.
*NSCLC, mixed histologies, or not specified.

Table 2. Surgical Procedures and Complete Resection (R0) Rates

Surgery	Surgery Alone (n = 168)		Preoperative Chemotherapy (n = 169)	
	Total Explored	R0	Total Explored	R0
All procedures	165	146*	152	142†
Pneumonectomy	26	24	24	21
Lobectomy	117	111	109	107
Bilobectomy	11	10	10	10
Wedge resection/segmentectomy	4	1	1	1
Resected, procedure not reported	0	0	3	3
Exploration, no resection	7	0	5	0

NOTE. Data are No. of patients, by intent to treat.

*Represents 88% of those who had exploration and 87% of those assigned to arm. Four of the completely resected (R0) patients had refused assigned arm and received preoperative chemotherapy (a major protocol violation). One patient who did not receive surgery had also refused assigned arm and received chemotherapy.

†Represents 93% of those who had exploration and 84% of those assigned to arm. One patient assigned to preoperative chemotherapy refused assigned arm and received surgery only, with microscopic residual disease (R1).

Table 3. Surgical Morbidity and Mortality for Patients Who Underwent Surgical Exploration

Parameter	Surgery Alone (n = 165)		Preoperative Chemotherapy (n = 152)	
	No.	%	No.	%
Operative morbidity				
Pneumonia	12	7	10	7
Reintubation	9	5	11	7
Tracheostomy	3	2	2	1
ICU readmission	10	6	8	5
Chest tube air leak	12	7	13	9
Respiratory failure	7	4	10	7
Atrial arrhythmia	27	16	24	16
Postoperative mortality, by type of surgery				
Lobectomy	3/117	3	3/109	3
Wedge resection	1/4	25	0/1	0
Pneumonectomy	0/26	0	4/24	17
Total	4/147	3	7/134	5

NOTE. Data are for patients who had a complication or died.
Abbreviation: ICU, intensive care unit.

violation). Fifteen (9%) of 169 patients randomly assigned to arm 2 were found to have pathologic complete response (no viable tumor in the resected specimen). This included two patients (of five) who had radiographic complete response, 10 with radiographic partial response and three with stable disease.

Table 2 presents surgical results by randomization arm. The surgical procedures performed did not differ significantly between the arms. The complete resection (R0) rates were also similar in the two groups. After exclusion of the five patients with major protocol violations, 87% of surgery-alone patients had complete resection versus 84% of those who received preoperative chemotherapy.

Surgical morbidity and mortality data are summarized in Table 3. There were 11 deaths after surgery. Four occurred in arm 1:3 after lobectomy and one after a wedge/chest wall resection. Causes of death were hemorrhage (postoperative day 4), sudden death (postoperative day 5), pneumonia (postoperative day 20), and multiple complications (postoperative day 5). Seven postoperative deaths occurred in arm 2: four after pneumonectomy (two right sided and two left sided) and three after lobectomy. Causes of death in the pneumonectomy patients were multiorgan failure (postoperative day 13), pneumonia/acute respiratory distress syndrome (ARDS; postoperative day 27), sudden death (postoperative day 30), and aspiration/ARDS/multiorgan failure (postoperative day 52); causes of death in the lobectomy patients were sudden death (postoperative day 9), sepsis/atrial fibrillation/multiorgan failure (postoperative day 15), and hemoptysis (postoperative day 15).

Survival

PFS. As of September 3, 2008, with a median follow-up of 64 months, PFS rates at 1, 3, and 5 years were 68%, 38%, and 33% in the surgery-alone group (arm 1) and 68%, 48%, and 42% in the preoperative chemotherapy and surgery group (arm 2; Fig 2). The median PFS was 20 months in arm 1 (95% CI, 17 to 28 months) and 33 months in arm 2 (95% CI, 21 to 48 months; hazard ratio [HR], 0.80; 95% CI, 0.61 to 1.04; $P = .10$).




Fig 2. Progression-free survival by treatment arm (median follow-up, 64 months). Pre-op, preoperative; chemo, chemotherapy; N, number.

Sites of first relapse are shown in Appendix Table A3 (online only). After exclusion of the 10 patients whose first relapse site was unknown, the estimated probabilities (by cumulative incidence analysis) of any distant recurrence at 12 and 24 months were 18% and 30% for arm 1 and 15% and 24% for arm 2, respectively. There were no significant differences in patterns of distant recurrence between the study arms. The risks of local-only recurrence at 12 and 24 months were 6% and 11% in arm 1 and 9% and 13% in arm 2. Survival after recurrence was similar in the two arms, with a median survival after progression of 12 months in the surgery-alone arm and 9 months in the preoperative chemotherapy arm ($P = .77$; 2-year postrelapse survival rates, 27% and 24%, respectively).

OS. As of September 3, 2008, with a median follow-up of 64 months, OS rates at 1, 3, and 5 years were 79%, 56%, and 41% in the surgery-alone arm and 82%, 61%, and 50% in the preoperative chemotherapy plus surgery arm (Fig 3). The median OS was 41 months in arm 1 (95% CI, 34 to 55 months) and 62 months in arm 2 (95% CI, 40 to 76 months). The HR for preoperative chemotherapy plus surgery versus surgery only was 0.79 (95% CI, 0.60 to 1.06; $P = .11$).

The influences of Zubrod performance status (0 v 1), stage (IB/IIA v IIB/IIIA), histology, and sex were examined with stepwise selection in a multivariate Cox regression model including treatment arm. Only stage (HR, 1.43; 95% CI, 1.05 to 1.96; $P = .025$ in favor of lower stage) and sex (HR, 1.69; 95% CI, 1.20 to 2.38; $P = .003$ in favor of




Fig 3. Overall survival by treatment arm (median follow-up, 64 months). Pre-op, preoperative; chemo, chemotherapy; N, number.

females) were found to be significantly prognostic for OS. Interactions between treatment arm and stage and between treatment arm and sex were not identified. The majority of patients enrolled were white (86%), and the remaining were African American (7%), Asian (< 1%), Native American (< 1%), or not reported (5%). This ethnic distribution precluded any meaningful analysis of treatment effect by ethnicity.

DISCUSSION

This prospective randomized trial found trends in favor of the use of preoperative chemotherapy followed by surgery versus surgery alone in early-stage NSCLC; however, the differences did not reach statistical significance. The absolute improvement in OS rate at 5 years was 9%, comparable with or better than differences observed with postoperative chemotherapy in operable NSCLC.^{10,11,13,14} This trial did not accrue its planned sample size because during its conduct, studies of postoperative chemotherapy found an OS benefit, establishing a new standard of care for resectable NSCLC.

The first reported phase III trial of preoperative chemotherapy for early-stage NSCLC was a French study¹⁵ that found chemotherapy led to an 11-month increase in median OS (37 v 26 months) and an 8.6% absolute increase in 4-year survival, but the differences were not statistically significant. With additional follow-up, the 3- and 5-year survival increases were stable at around 10% ($P = .04$ at 3 years; $P = .06$ at 5 years), and statistically significant benefits from preoperative chemotherapy in the N0/N1 subgroup were confirmed (5-year OS rate, 49% v 34%; $P = .02$).¹⁶

A Scandinavian randomized trial¹⁷ of preoperative chemotherapy in early-stage NSCLC closed prematurely after slow accrual (90 patients in 6 years). The median and 5-year OS rates were 34 months and 36% for preoperative chemotherapy versus 23 months and 24% for surgery alone (differences not significant). A large United King-

dom trial found no difference in extent of surgical procedures performed, operative morbidity and mortality, or survival between patients randomly assigned to preoperative chemotherapy versus surgery alone (HR, 1.02; 95% CI, 0.8 to 1.31).¹⁸

The Chemotherapy in Early stages NSCLC Trial (ChEST) was unique among randomized trials of preoperative chemotherapy as its primary end point was PFS. Similar to the S9900 trial, ChEST closed early after accruing 270 of 700 planned patients. The median PFS and 3-year PFS rate were 2.9 years and 48% for surgery alone versus 4.0 years and 53% for preoperative chemotherapy and surgery ($P = .109$; HR, 0.71; 95% CI, 0.50 to 0.99; $P = .011$). OS results also favored preoperative chemotherapy. However, subset analyses found these benefits restricted to the stage IIB/IIIA patients.¹⁹ The ChEST findings were not consistent with the S9900 subset analysis, in which no treatment arm and stage interaction was found, or the French trial,¹⁵ in which the N0/N1 patients experienced a greater benefit from chemotherapy. To our knowledge, the ChEST trial is the only preoperative chemotherapy trial to date in which the pneumonectomy rate was lower in patients receiving preoperative therapy. In our trial, pneumonectomy rates were similar in the two treatment arms.

The three-arm NATCH (Neoadjuvant/Adjuvant Taxol/Carboplatin Hope) trial, which accrued 624 patients compared disease-free survival with surgery alone versus three cycles of preoperative or postoperative paclitaxel/carboplatin chemotherapy and surgery in early-stage NSCLC.²⁰ Similar to our study, there were no differences in complete resection rates, surgical procedures, or operative mortality. At 51 months of follow-up, the disease-free survival tended to favor chemotherapy, with an HR of 0.92 for preoperative chemotherapy (95% CI, 0.81 to 1.04; $P = .18$) and an HR of 0.96 for postoperative chemotherapy (95% CI, 0.75 to 1.22; $P = .73$).²⁰

Table 4^{1-4,15-20} summarizes the results of the previously reported phase III trials of preoperative chemotherapy for operable NSCLC.

Table 4. Randomized Trials of Preoperative Chemotherapy in Operable Non-Small-Cell Lung Cancer

First Author	Stage	Regimen	No. of Patients	Radiographic Response Rate (%)	Complete Resection Rate (%)	Median OS (months)	5-Year OS (%)
Roth ^{1,2}	IIIA	CEP	28	35	39	21	36
		Surgery	32	—	31	14	15
Rosell ^{3,4}	IIIA	MIP	30	60	77	22	17
		Surgery	30	—	90	10	0
DePierre ^{15,16}	IB, II, IIIA (+N2)	MIP	179	64	92	37	41
		Surgery	176	—	86	26	32
Sorensen ¹⁷	IB, II, IIIA	PacCb	44	46	79	34	36
		Surgery	46	—	70	23	24
Gilligan ¹⁸	I, II, III	Platin +	258	49	NR	53	44
		Surgery	261	—	NR	54	45
This study	IB, II, IIIA	PacCb	169	41	84	62	50
		Surgery	167	—	87	41	41
Scagliotti ¹⁹	IB, II, IIIA	GP	129	35	NR	58	67*
		Surgery	141	—	NR	Unest	60*
Felip ²⁰	I, II, IIIA	Preop PacCb	199	59	87	55	47
		Surgery	210	—	90	49	44
		Postop PacCb	210	—	90	50	46

Abbreviations: OS, overall survival; CEP, cyclophosphamide, etoposide, and cisplatin; MIP, mitomycin, ifosfamide, cisplatin; PacCb, paclitaxel, carboplatin; Platin +, vinorelbine/cisplatin, gemcitabine/cisplatin, mitomycin/vinblastine/cisplatin, docetaxel/carboplatin, or mitomycin/ifosfamide/cisplatin; GP, gemcitabine, cisplatin; Preop, preoperative; Postop, postoperative; NR, not reported; Unest, unestimated.

*Three-year progression-free survival rates.

With the exception of the LU22 trial,¹⁸ all studies found survival trends in favor of preoperative chemotherapy; the benefits seen were comparable in magnitude to those achieved with postoperative chemotherapy. Two meta-analyses have also examined the efficacy of chemotherapy in resectable NSCLC.^{21,22} Both meta-analyses were based on data extracted from abstracts and manuscripts, a method considered inferior to meta-analyses of individual patient data; thus, the results should be interpreted with caution.²³ Berghmans et al²¹ found an OS HR of 0.66 for preoperative chemotherapy (95% CI, 0.48 to 0.93) and an HR of 0.84 for postoperative chemotherapy (95% CI, 0.78 to 0.89). The Burdett et al²² meta-analysis found an OS HR of 0.82 (95% CI, 0.69 to 0.97; $P = .02$) with an absolute benefit of 6% at 5 years for preoperative chemotherapy in randomized trials.

A meta-analysis directly comparing the efficacy of postoperative versus preoperative chemotherapy for resectable NSCLC in randomized trials found an OS HR of 0.80 for postoperative chemotherapy (95% CI, 0.73 to 0.87) and 0.81 for preoperative chemotherapy (95% CI, 0.68 to 0.97). Using indirect comparison meta-analysis, the relative hazard of postoperative compared with preoperative chemotherapy was 0.99 (95% CI, 0.81 to 1.21; $P = .900$). Findings were similar for disease-free survival. The authors concluded that postoperative and preoperative chemotherapy yielded similar survival benefits.²⁴

Concerns have been raised that preoperative chemotherapy increases surgical morbidity and mortality. In this and other trials, surgical complication rates after preoperative chemotherapy were similar to rates observed after surgery alone. However, postoperative mortality rates were higher in patients who underwent pneumonectomy after preoperative therapy.^{25,26}

Although the observed benefits of preoperative and postoperative chemotherapy in the reported phase III trials and meta-analysis appear similar, one must consider inherent differences as a consequence of modality sequencing. The delivery of preoperative chemotherapy is intended to increase the percentage of patients who receive systemic therapy without interfering with the percentage who receive surgery. In contrast, when surgery is the initial modality, estimates are that fewer than 75% of patients initially eligible for preoperative chemotherapy and surgery ultimately receive postoperative chemotherapy. In the NATCH trial,²⁰ 90% of patients completed three cycles of chemotherapy in the preoperative chemotherapy arm, compared with 66% of patients in the postoperative chemotherapy arm. By increasing the percentage of patients who actually receive chemotherapy, the preoperative chemotherapy strategy may yield superior survival results. Unfortunately, a prospective, randomized, phase III trial addressing this question failed to accrue sufficient patients in the United States. Although a subset of patients may benefit from a preoperative strategy, this is not yet defined.

In conclusion, phase III trials of preoperative chemotherapy for operable NSCLC support its use with survival benefits comparable to

those seen with postoperative chemotherapy. The S9900 study found a 21% reduction in the risk of death and a 9% improvement in 5-year OS rate with three cycles of preoperative paclitaxel and carboplatin, although these improvements were not statistically significant. Based on clinical trial data available at this time, stronger evidence exists supporting the use of postoperative chemotherapy in patients with resectable NSCLC.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: None **Consultant or Advisory Role:** Eric Vallières, Bristol-Myers Squibb (U); Paul A. Bunn Jr, AstraZeneca (C), ImClone Systems (C), Eli Lilly (C), GlaxoSmithKline (C), Amgen (C), Genentech (C), sanofi-aventis (C), Boehringer Ingelheim (C), Bristol-Myers Squibb (C), OSI Pharmaceuticals (C), Roche (C); David Gandara, Bristol-Myers Squibb (C), Genentech (C), AstraZeneca (U), sanofi-aventis (C), Bayer Pharmaceuticals (C), Response Genetics (U) **Stock Ownership:** None **Honoraria:** Eric Vallières, Bristol-Myers Squibb; Paul A. Bunn Jr, AstraZeneca, ImClone Systems, Eli Lilly, GlaxoSmithKline, Amgen, Genentech, sanofi-aventis, Boehringer Ingelheim, Bristol-Myers Squibb, OSI Pharmaceuticals, Roche; Joe B. Putnam Jr, Bristol-Myers Squibb; David Gandara, Genentech, Bristol-Myers Squibb **Research Funding:** David Gandara, Bristol-Myers Squibb, Eli Lilly, Pfizer **Expert Testimony:** None **Other Remuneration:** None

AUTHOR CONTRIBUTIONS

Conception and design: Katherine M.W. Pisters, John J. Crowley, Wilbur A. Franklin, Paul A. Bunn Jr, Robert J. Ginsberg, David Gandara **Administrative support:** Eric Vallières, Wilbur A. Franklin **Provision of study materials or patients:** Katherine M.W. Pisters, Eric Vallières, Paul A. Bunn Jr, Joe B. Putnam Jr, David Gandara **Collection and assembly of data:** Katherine M.W. Pisters, Eric Vallières, John J. Crowley, Wilbur A. Franklin, Paul A. Bunn Jr, Kari Chansky **Data analysis and interpretation:** Katherine M.W. Pisters, Eric Vallières, John J. Crowley, Paul A. Bunn Jr, Kari Chansky **Manuscript writing:** Katherine M.W. Pisters, Eric Vallières, John J. Crowley, Paul A. Bunn Jr, Kari Chansky, David Gandara **Final approval of manuscript:** Katherine M.W. Pisters, Eric Vallières, John J. Crowley, Wilbur A. Franklin, Paul A. Bunn Jr, Joe B. Putnam Jr, Kari Chansky, David Gandara

REFERENCES

- Roth J, Fossella F, Komaki R, et al: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. *J Natl Cancer Inst* 86: 673-680, 1994
- Roth J, Atkinson E, Fossella F, et al: Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and sur-

gery with surgery alone in resectable stage IIIA non-small cell lung cancer. *Lung Cancer* 21:1-6, 1998

3. Rosell R, Gomez-Codina J, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. *N Engl J Med* 330:153-158, 1994

4. Rosell R, Gomez-Codina J, Camps C, et al: Preoperative chemotherapy in stage IIIA non-small cell lung cancer: A 7-year assessment of a randomized controlled trial. *Lung Cancer* 47:7-14, 1999

5. Dillman R, Seagren S, Herndon J, et al: Improved survival in stage III non-small cell lung cancer: Seven-year follow-up of CALGB 8433. *J Natl Cancer Inst* 88:1210-1215, 1996

6. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group 88-08 and Eastern Cooperative Oncology Group 4588: Preliminary results of a phase III trial of regionally advanced, unresectable non-small cell lung cancer. *J Natl Cancer Inst* 87:198-205, 1995

7. Pisters KM, Ginsberg RJ, Giroux DJ, et al: Induction chemotherapy before surgery for early-stage

lung cancer: A novel approach: Bimodality Lung Oncology Team. *J Thorac Cardiovasc Surg* 119:429-439, 2000

8. Reference deleted

9. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. *J Natl Cancer Inst* 92:205-216, 2000

10. The International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. *N Engl J Med* 350:351-360, 2004

11. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. *N Engl J Med* 353:2589-2597, 2005

12. Strauss GM, Herndon J, Maddaus MA, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. 22:621s, 2004 (suppl; abstr 7019)

13. Douillard J, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIa non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomized controlled trial. *Lancet Oncol* 7:719-727, 2006

14. Pignon J, Tribodet H, Scagliotti GV, et al: A pooled analysis of five randomized clinical trials including 4,584 patients. *J Clin Oncol* 24:366s, 2006 (suppl; abstr 7008)

15. Depierre A, Milleron B, Moro-Sibilot D, et al: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small cell lung cancer. *J Clin Oncol* 20:247-253, 2001

16. Depierre A, Westeel V, Milleron B, et al: 5 year results of the French randomized study comparing preoperative chemotherapy followed by surgery and primary surgery in resectable stage I (except T1N0), II and IIIa non-small cell lung cancer. *Lung Cancer* 41:S62, 2003 (suppl 2; abstr O-211)

17. Sorensen JB, Riska H, Ravn J, et al: Scandinavian phase III trial of neoadjuvant chemotherapy in NSCLC stages IB-IIIa/T3. *J Clin Oncol* 24:400s, 2006 (suppl; abstr 7146)

18. Gilligan D, Nicolson M, Smith I, et al: Preoperative chemotherapy in patients with resectable non-small cell lung cancer: Results of the MRC LU22/NVALT/EORTC 08012 multicentre randomized trial and update of systematic review. *Lancet* 369:1929-1937, 2007

19. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al: A phase III randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): Follow-up data of ChEST. *J Clin Oncol* 26:399s, 2008 (suppl; abstr 7508)

20. Felip E, Massuli B, Alonso G, et al: Surgery alone, preoperative paclitaxel/carboplatin chemotherapy followed by surgery, or surgery followed by adjuvant paclitaxel/carboplatin chemotherapy in early stage non-small cell lung cancer: Results of the

NATCH multicentre randomized, phase III trial. *J Clin Oncol* 27:382s, 2009 (suppl; abstr 7500)

21. Berghmans T, Paesmans M, Meert A, et al: Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature. *Lung Cancer* 49:13-23, 2005

22. Burdett S, Stewart L, Rydzewska L: A systematic review and meta-analysis of the literature: Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. *J Thorac Oncol* 1:611-621, 2006

23. Piedbois P, Buyse M: Meta-analyses based on abstracted data: A step in the right direction, but only a first step. *J Clin Oncol* 22:3839-3840, 2004

24. Lim E, Harris G, Patel A, et al: Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: Systematic review and indirect comparison meta-analysis of randomized trials. *J Clin Oncol* 26:408s, 2008 (suppl; abstr 7546)

25. Martin J, Ginsberg R, Abolhoda A, et al: Morbidity and mortality after neoadjuvant therapy for lung cancer: The risks of right pneumonectomy. *Ann Thorac Surg* 72:1149-1154, 2001

26. Rusch V, Albain K, Turrisi A, et al: Phase III trial of concurrent chemotherapy and radiotherapy (CT/RT) versus CT/RT followed by surgical resection for stage IIIA-N2 non-small cell lung cancer: Outcomes and implications for surgical management in North American Intergroup 0139 (RTOG 9309). *Lung Cancer* 49:S15, 2005 (suppl 2; abstr O-035)



Journal of Oncology Practice Now Available on PubMed Central

Beginning with the January 2010 issue, full text for all *JOP* articles will be available on the NIH PubMed Central archive 4 months after publication. Once available, content is then delivered to PubMed, a metadata repository overseen by the National Library of Medicine and used by many scientific, technical, and medical researchers, making *JOP* material discoverable in PubMed for the first time.

Find yourself in PubMed. Submit your manuscript to *JOP* at jopsubmissions@asco.org.



American Society of Clinical Oncology